BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 30152050)

  • 1. Comparative study between
    Wong HS; Leung J; Bartholomeusz D; Sutherland P; Le H; Nottage M; Iankov I; Chang JH
    J Med Imaging Radiat Oncol; 2018 Dec; 62(6):816-822. PubMed ID: 30152050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
    Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG
    Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of
    Ferraro DA; Garcia Schüler HI; Muehlematter UJ; Eberli D; Müller J; Müller A; Gablinger R; Kranzbühler H; Omlin A; Kaufmann PA; Hermanns T; Burger IA
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):652-664. PubMed ID: 31802175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity, Specificity, and Predictors of Positive
    Perera M; Papa N; Christidis D; Wetherell D; Hofman MS; Murphy DG; Bolton D; Lawrentschuk N
    Eur Urol; 2016 Dec; 70(6):926-937. PubMed ID: 27363387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?
    Kulkarni SC; Sundaram PS; Padma S
    Nucl Med Commun; 2020 Feb; 41(2):139-146. PubMed ID: 31714366
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
    Ergül N; Yilmaz Güneş B; Yücetaş U; Toktaş MG; Çermik TF
    Clin Nucl Med; 2018 Dec; 43(12):e422-e427. PubMed ID: 30273204
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Ceci F; Castellucci P; Graziani T; Farolfi A; Fonti C; Lodi F; Fanti S
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Impact of
    Calais J; Kishan AU; Cao M; Fendler WP; Eiber M; Herrmann K; Ceci F; Reiter RE; Rettig MB; Hegde JV; Shaverdian N; King CR; Steinberg ML; Czernin J; Nickols NG
    J Nucl Med; 2018 Nov; 59(11):1714-1721. PubMed ID: 29653978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer.
    Tulsyan S; Das CJ; Tripathi M; Seth A; Kumar R; Bal C
    Nucl Med Commun; 2017 Dec; 38(12):1094-1102. PubMed ID: 28957842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [
    Green MA; Hutchins GD; Bahler CD; Tann M; Mathias CJ; Territo W; Sims J; Polson H; Alexoff D; Eckelman WC; Kung HF; Fletcher JW
    Mol Imaging Biol; 2020 Jun; 22(3):752-763. PubMed ID: 31429050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of
    Sonni I; Eiber M; Fendler WP; Alano RM; Vangala SS; Kishan AU; Nickols N; Rettig MB; Reiter RE; Czernin J; Calais J
    J Nucl Med; 2020 Aug; 61(8):1153-1160. PubMed ID: 31924715
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Corfield J; Perera M; Bolton D; Lawrentschuk N
    World J Urol; 2018 Apr; 36(4):519-527. PubMed ID: 29344682
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Hruby G; Eade T; Emmett L; Ho B; Hsiao E; Schembri G; Guo L; Kwong C; Hunter J; Byrne K; Kneebone A
    Asia Pac J Clin Oncol; 2018 Aug; 14(4):343-346. PubMed ID: 29663686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
    Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M
    J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Vinsensia M; Chyoke PL; Hadaschik B; Holland-Letz T; Moltz J; Kopka K; Rauscher I; Mier W; Schwaiger M; Haberkorn U; Mauer T; Kratochwil C; Eiber M; Giesel FL
    J Nucl Med; 2017 Dec; 58(12):1949-1955. PubMed ID: 28637799
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer.
    Yilmaz B; Turkay R; Colakoglu Y; Baytekin HF; Ergul N; Sahin S; Tugcu V; Inci E; Tasci AI; Cermik TF
    Prostate; 2019 Jun; 79(9):1007-1017. PubMed ID: 31012125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study.
    Dewes S; Schiller K; Sauter K; Eiber M; Maurer T; Schwaiger M; Gschwend JE; Combs SE; Habl G
    Radiat Oncol; 2016 May; 11():73. PubMed ID: 27229485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Staging
    Wu SY; Boreta L; Shinohara K; Nguyen H; Gottschalk AR; Hsu IC; Roach M; Westphalen AC; Feng FY; Carroll PR; Chang AJ; Hope TA
    Urology; 2019 Mar; 125():154-162. PubMed ID: 30580002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.